BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:FCN-338 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of FCN-338\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06858618-3078@assetmemo.bio
DTSTAMP:20261121T005809Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:FCN-338: Phase 2 readout est. (NCT06858618)
DESCRIPTION:FCN-338\, phase 2.\nStudy: FCN-338 in Combination With Azacitid
 ine or Chemotherapy in Myeloid Neoplasms\nEstimated primary completion: 1 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fcn-33
 8#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 858618
URL:https://assetmemo.bio/drug/fcn-338#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
